REGEnLIFE SAS
REGEnLIFE develops a cutting-edge photomedical neurotechnology for the treatment of neurodegenerative diseases. REGEnLIFE is a late-stage medical technology company currently focused on the treatment of Alzheimer's disease and mild traumatic brain injury (which can lead to dementia). The medical device is a patented therapeutic solution based on biophotonics. This non-invasive and painless application targets both the brain and the gut. Recent scientific studies suggest that the brain-gut axis plays a key role in the development of neurodegenerative diseases.
Industries
Nr. of Employees
small (1-50)
Products
RGn530
A medical device utilizing Tri-Photon stimulation for treating neurodegenerative diseases by targeting multiple areas (Brain/Gut).
Light4life
A pivotal clinical study to assess the therapeutic efficacy of photomedical technology in Alzheimer's disease.
Photobiomodulation technology
A non-invasive, drug-free medical approach based on physical sciences for treating neurodegenerative diseases.
Neurotechnology R&D
Research and development in neurotechnology for creating innovative medical devices against Alzheimer's and other neurological conditions.
RGn530
A medical device utilizing Tri-Photon stimulation for treating neurodegenerative diseases by targeting multiple areas (Brain/Gut).
Light4life
A pivotal clinical study to assess the therapeutic efficacy of photomedical technology in Alzheimer's disease.
Photobiomodulation technology
A non-invasive, drug-free medical approach based on physical sciences for treating neurodegenerative diseases.
Neurotechnology R&D
Research and development in neurotechnology for creating innovative medical devices against Alzheimer's and other neurological conditions.
Expertise Areas
- Digital engagement
- Web-based user support
Key Technologies
- Social media widget iframe embedding
- Web-based contact and FAQ pages